International union of pharmacology. LXIII. Retinoid X receptors

Pharmacological Reviews

Volumn 58, Issue 4, 2006, Pages 760-772

  Germain, Pierre ^a,b   Chambon, Pierre ^a,b   Eichele, Gregor ^c   Evans, Ronald M ^d   Lazar, Mitchell A ^e   Leid, Mark ^f   De Lera, Angel R ^g   Lotan, Reuben ^h   Mangelsdorf, David J ⁱ   Gronemeyer, Hinrich ^a,b  

^a INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b Communauté Urbaine de Strasbourg ^*  (France)

^c MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY   (Germany)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f OREGON STATE UNIVERSITY   (United States)

^g UNIVERSITY OF VIGO   (Spain)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 METHYL 7 (5,6,7,8 TETRAHYDRO 5,5,8,8 TETRAMETHYL 3 PROPOXY 2 NAPHTHYL) 2,4,6 OCTATRIENOIC ACID; 4 [2 (5,6,7,8 TETRAHYDRO 5,5,8,8 TETRAMETHYL 2 NAPHTHYL) 1,3 DIOXOLAN 2 YL]BENZOIC ACID; 6 [1 (5,6,7,8 TETRAHYDRO 3,5,5,8,8 PENTAMETHYL 2 NAPHTHYL)CYCLOPROPYL]NICOTINIC ACID; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; AGN 194204; ALITRETINOIN; BEXAROTENE; CD 3254; CELL NUCLEUS RECEPTOR; DOCOSAHEXAENOIC ACID; LIGAND; METHOPRENE; PA 451; PHYTANIC ACID; RETINOID; RETINOID X RECEPTOR; RETINOID X RECEPTOR AFFECTING AGENT; RETINOID X RECEPTOR ALPHA; RETINOID X RECEPTOR BETA; RETINOID X RECEPTOR BLOCKING AGENT; RETINOID X RECEPTOR GAMMA; REXINOID DERIVATIVE; UV 13003; UVI 3003;

CANCER; CLINICAL TRIAL; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; ENDOCRINE DISEASE; GENE TARGETING; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; METABOLIC DISORDER; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVIEW; SIDE EFFECT; SKIN DISEASE; STEREOISOMERISM; T CELL LYMPHOMA; UNSPECIFIED SIDE EFFECT;

ANIMALS; GENE EXPRESSION; HUMANS; LIGANDS; MUTATION; RETINOID X RECEPTORS; RETINOIDS; TERMINOLOGY;

EID: 33751533155     PISSN: 00316997     EISSN: 15210081     Source Type: Journal    
DOI: 10.1124/pr.58.4.7     Document Type: Review

References (112)

1. Allenby G, Bocquel MT, Saunders M, Kazmer S, Speck J, Rosenberger M, Lovey A, Kastner P, Grippo JF, Chambon P, and et al (1993) Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci USA 90:30-34.
2. Altucci L and Gronemeyer H (2001) The promise of retinoids to fight against cancer. Nat Rev Cancer 1:181-193.
3. Altucci L, Rossin A, Hirsch O, Nebbioso A, Vitoux D, Wilhelm E, Guidez F, De Simone M, Schiavone EM, Grimwade D, et al. (2005) Rexinoid-triggered differentiation and tumor-selective apoptosis of acute myeloid leukemia by protein kinase A-mediated desubordination of retinoid X receptor. Cancer Res 65:8754-8765.
4. Apfel CM, Kamber M, Klaus M, Mohr P, Keidel S, and LeMotte PK (1995) Enhancement of HL-60 differentiation by a new class of retinoids with selective activity on retinoid X receptor. J Biol Chem 270:30765-30772.
5. Benoit G, Altucci L, Flexor M, Ruchaud S, Lillehaug J, Raffelsberger W, Gronemeyer H, and Lanotte M (1999) RAR-independent RXR signaling induces t(15;17) leukemia cell maturation. EMBO (Eur Mol Biol Organ) J 18:7011-7018.
6. Berger J, Biswas C, Hayes N, Ventre J, Wu M, and Doebber TW (1996) An antidiabetic thiazolidinedione potentiates insulin stimulation of glycogen synthase in rat adipose tissues. Endocrinology 137:1984-1990.
7. Boehm MF, Zhang L, Badea BA, White SK, Mais DE, Berger E, Suto CM, Goldman ME, and Heyman RA (1994) Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids. J Med Chem 37:2930-2941.
8. Boehm MF, Zhang L, Zhi L, McClurg MR, Berger E, Wagoner M, Mais DE, Suto CM, Davies JA, Heyman RA, et al. (1995) Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells. J Med Chem 38:3146-3155.
9. Bourguet W, Vivat V, Wurtz JM, Chambon P, Gronemeyer H, and Moras D (2000) Crystal structure of a heterodimeric complex of RAR and RXR ligand-binding domains. Mol Cell 5:289-298.
10. Brocard J, Kastner P, and Chambon P (1996) Two novel RXRα isoforms from mouse testis. Biochem Biophys Res Commun 229:211-218.
11. Brown NS, Smart A, Sharma V, Brinkmeier ML, Greenlee L, Camper SA, Jensen DR, Eckel RH, Krezel W, Chambon P, et al. (2000) Thyroid hormone resistance and increased metabolic rate in the RXR-γ-deficient mouse. J Clin Investig 106:73-79.
12. Cesario RM, Klausing K, Razzaghi H, Crombie D, Rungta D, Heyman RA, and Lala DS (2001) The rexinoid LG100754 is a novel RXR:PPARγ agonist and decreases glucose levels in vivo. Mol Endocrinol 15:1360-1369.
13. Cha BS, Ciaraldi TP, Carter L, Nikoulina SE, Mudaliar S, Mukherjee R, Paterniti JR Jr, and Henry RR (2001) Peroxisome proliferator-activated receptor (PPAR) γ and retinoid X receptor (RXR) agonists have complementary effects on glucose and lipid metabolism in human skeletal muscle. Diabetologia 44:444-452.
14. Chambon P (1996) A decade of molecular biology of retinoic acid receptors. FASEB J 10:940-954.
15. Chawla A, Repa JJ, Evans RM, and Mangelsdorf DJ (2001) Nuclear receptors and lipid physiology: opening the X-files. Science (Wash DC) 294:1866-1870.
16. Chen JY, Clifford J, Zusi C, Starrett J, Tortolani D, Ostrowski J, Reczek PR, Chambon P, and Gronemeyer H (1996) Two distinct actions of retinoid-receptor ligands. Nature (Lond) 382:819-822.
17. Cheskis B and Freedman LP (1996) Modulation of nuclear receptor interactions by ligands: kinetic analysis using surface plasmon resonance. Biochemistry 35:3309-3318.
18. Chiang MY, Misner D, Kempermann G, Schikorski T, Giguere V, Sucov HM, Gage FH, Stevens CF, and Evans RM (1998) An essential role for retinoid receptors RARβ and RXRγ in long-term potentiation and depression. Neuron 21:1353-1361.
19. Chiba H, Clifford J, Metzger D, and Chambon P (1997) Distinct retinoid X receptor-retinoic acid receptor heterodimers are differentially involved in the control of expression of retinoid target genes in F9 embryonal carcinoma cells. Mol Cell Biol 17:3013-3020.
20. Clarke N, Germain P, Altucci L, and Gronemeyer H (2004) Retinoids: potential in cancer prevention and therapy. Expert Rev Mol Med 6:1-23.
21. Clifford J, Chiba H, Sobieszczuk D, Metzger D, and Chambon P (1996) RXRα-null F9 embryonal carcinoma cells are resistant to the differentiation, anti-proliferative and apoptotic effects of retinoids. EMBO (Eur Mol Biol Organ) J 15:4142-4155.
22. Crowe DL and Chandraratna RA (2004) A retinoid X receptor (RXR)-selective retinoid reveals that RXR-α is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands. Breast Cancer Res 6:R546-R555.
23. Dawson MI (2004) Synthetic retinoids and their nuclear receptors. Curr Med Chem Anticancer Agents 4:199-230.
24. de Urquiza AM, Liu S, Sjoberg M, Zetterstrom RH, Griffiths W, Sjovall J, and Perlmann T (2000) Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain. Science (Wash DC) 290:2140-2144.
25. Dolle P, Fraulob V, Kastner P, and Chambon P (1994) Developmental expression of murine retinoid X receptor (RXR) genes. Mech Dev 45:91-104.
26. Dragnev KH, Petty WJ, Shah S, Biddle A, Desai NB, Memoli V, Rigas JR, and Dmitrovsky E (2005) Bexarotene and erlotinib for aerodigestive tract cancer. J Clin Oncol 23:8757-8764.
27. Egea PF, Mitschler A, and Moras D (2002) Molecular recognition of agonist ligands by RXRs. Mol Endocrinol 16:987-997.
28. Fleischhauer K, Park JH, DiSanto JP, Marks M, Ozato K, and Yang SY (1992) Isolation of a full-length cDNA clone encoding a N-terminally variant form of the human retinoid X receptor β. Nucleic Acids Res 20:1801.
29. Forman BM (2002) The antidiabetic agent LG100754 sensitizes cells to low concentrations of peroxisome proliferator-activated receptor γ ligands. J Biol Chem 277:12503-12506.
30. Forman BM, Umesono K, Chen J, and Evans RM (1995) Unique response pathways are established by allosteric interactions among nuclear hormone receptors. Cell 81:541-550.
31. Germain P, Iyer J, Zechel C, and Gronemeyer H (2002) Coregulator recruitment and the mechanism of retinoic acid receptor synergy. Nature (Lond) 415:187-192.
32. Germain P, Kammerer S, Perez E, Peluso-Iltis C, Tortolani D, Zusi FC, Starrett J, Lapointe P, Daris JP, Marinier A, et al. (2004) Rational design of RAR-selective ligands revealed by RARβ crystal stucture. EMBO Rep 5:877-882.
33. Glass CK (1994) Differential recognition of target genes by nuclear receptor monomers, dimers, and heterodimers. Endocr Rev 15:391-407.
34. Gronemeyer H, Gustafsson JA, and Laudet V (2004) Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov 3:950-964.
35. Hamada K, Gleason SL, Levi BZ, Hirschfeld S, Appella E, and Ozato K (1989) H-2RIIBP, a member of the nuclear hormone receptor superfamily that binds to both the regulatory element of major histocompatibility class I genes and the estrogen response element. Proc Natl Acad Sci USA 86:8289-8293.
36. Haugen BR, Brown NS, Wood WM, Gordon DF, and Ridgway EC (1997) The thyrotrope-restricted isoform of the retinoid-X receptor-γ1 mediates 9-cis-retinoic acid suppression of thyrotropin-β promoter activity. Mol Endocrinol 11:481-489.
37. Heald P (2000) The treatment of cutaneous T-cell lymphoma with a novel retinoid. Clin Lymphoma 1 (Suppl 1):S45-S49.
38. Heyman RA, Mangelsdorf DJ, Dyck JA, Stein RB, Eichele G, Evans RM, and Thaller C (1992) 9-cis Retinoic acid is a high affinity ligand for the retinoid X receptor. Cell 68:397-406.
39. Hurst RE (2000) Bexarotene ligand pharmaceuticals. Curr Opin Investig Drugs 1:514-523.
40. Ijpenberg A, Tan NS, Gelman L, Kersten S, Seydoux J, Xu J, Metzger D, Canaple L, Chambon P, Wahli W, et al. (2004) In vivo activation of PPAR target genes by RXR homodimers. EMBO (Eur Mol Biol Organ) J 23:2083-2091.
41. Kagechika H and Shudo K (2005) Synthetic retinoids: recent developments concerning structure and clinical utility. J Med Chem 48:5875-5883.
42. Kastner P, Grondona JM, Mark M, Gansmuller A, LeMeur M, Decimo D, Vonesch JL, Dolle P, and Chambon P (1994) Genetic analysis of RXR α developmental function: convergence of RXR and RAR signaling pathways in heart and eye morphogenesis. Cell 78:987-1003.
43. Kastner P, Mark M, and Chambon P (1995) Nonsteroid nuclear receptors: what are genetic studies telling us about their role in real life? Cell 83:859-869.
44. Kastner P, Mark M, Leid M, Gansmuller A, Chin W, Grondona JM, Decimo D, Krezel W, Dierich A, and Chambon P (1996) Abnormal spermatogenesis in RXRβ mutant mice. Genes Dev 10:80-92.
45. Kastner P, Messaddeq N, Mark M, Wendling O, Grondona JM, Ward S, Ghyselinck N, and Chambon P (1997) Vitamin A deficiency and mutations of RXRα, RXRβ and RARα lead to early differentiation of embryonic ventricular cardiomyocytes. Development 124:4749-4758.
46. Kempf W, Kettelhack N, Duvic M, and Burg G (2003) Topical and systemic retinoid therapy for cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 17:1405-1419.
47. Klaholz BP, Renaud JP, Mitschler A, Zusi C, Chambon P, Gronemeyer H, and Moras D (1998) Conformational adaptation of agonists to the human nuclear receptor RARγ. Nat Struct Biol 5:199-202.
48. -/- mutant mice are viable. Proc Natl Acad Sci USA 93:9010-9014.
49. Krezel W, Ghyselinck N, Samad TA, Dupe V, Kastner P, Borrelli E, and Chambon P (1998) Impaired locomotion and dopamine signaling in retinoid receptor mutant mice. Science (Wash DC) 279:863-867.
50. Lala DS, Mukherjee R, Schulman IG, Koch SS, Dardashti LJ, Nadzan AM, Croston GE, Evans RM, and Heyman RA (1996) Activation of specific RXR heterodimers by an antagonist of RXR homodimers. Nature (Lond) 383:450-453.
51. Lampen A, Meyer S, and Nau H (2001) Phytanic acid and docosahexaenoic acid increase the metabolism of all-trans-retinoic acid and CYP26 gene expression in intestinal cells. Biochim Biophys Acta 1521:97-106.
52. Laudet V and Gronemeyer H (2002) The Nuclear Receptor Facts Book, Academic Press, San Diego.
53. Laudet V, Hanni C, Coll J, Catzeflis F, and Stehelin D (1992) Evolution of the nuclear receptor gene superfamily. EMBO (Eur Mol Biol Organ) J 11:1003-1013.
54. Leblanc BP and Stunnenberg HG (1995) 9-cis retinoic acid signaling: changing partners causes some excitement. Genes Dev 9:1811-1816.
55. Lehmann JM, Jong L, Fanjul A, Cameron JF, Lu XP, Haefner P, Dawson MI, and Pfahl M (1992) Retinoids selective for retinoid X receptor response pathways. Science (Wash DC) 258:1944-1946.
56. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, and Kliewer SA (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 270:12953-12956.
57. Leibowitz MD, Ardecky RJ, Boehm MF, Broderick CL, Carfagna MA, Crombie DL, D'Arrigo J, Etgen GJ, Faul MM, Grese TA, et al. (2006) Biological characterization of a heterodimer selective RXR modulator: potential benefits for the treatment of type 2 diabetes. Endocrinology 147:1044-1053.
58. Leid M, Kastner P, Lyons R, Nakshatri H, Saunders M, Zacharewski T, Chen JY, Staub A, Garnier JM, Mader S, et al. (1992) Purification, cloning, and RXR identity of the HeLa cell factor with which RAR or TR heterodimerizes to bind target sequences efficiently. Cell 68:377-395.
59. Lemotte PK, Keidel S, and Apfel CM (1996) Phytanic acid is a retinoid X receptor ligand. Eur J Biochem 236:328-333.
60. Lenhard JM, Lancaster ME, Paulik MA, Weiel JE, Binz JG, Sundseth SS, Gaskill BA, Lightfoot RM, and Brown HR (1999) The RXR agonist LG100268 causes hepatomegaly, improves glycaemic control and decreases cardiovascular risk and cachexia in diabetic mice suffering from pancreatic β-cell dysfunction. Diabetologia 42:545-554.
61. Levin AA, Sturzenbecker LJ, Kazmer S, Bosakowski T, Huselton C, Allenby G, Speck J, Kratzeisen C, Rosenberger M, Lovey A, et al. (1992) 9-cis retinoic acid stereoisomer binds and activates the nuclear receptor RXRα. Nature (Lond) 355:359-361.
62. Li M, Chiba H, Warot X, Messaddeq N, Gerard C, Chambon P, and Metzger D (2001) RXR-α ablation in skin keratinocytes results in alopecia and epidermal alterations. Development 128:675-688.
63. Li M, Indra AK, Warot X, Brocard J, Messaddeq N, Kato S, Metzger D, and Chambon P (2000) Skin abnormalities generated by temporally controlled RXRα mutations in mouse epidermis. Nature (Lond) 407:633-636.
64. Li M, Messaddeq N, Teletin M, Pasquali JL, Metzger D, and Chambon P (2005) Retinoid X receptor ablation in adult mouse keratinocytes generates an atopic dermatitis triggered by thymic stromal lymphopoietin. Proc Natl Acad Sci USA 102:14795-14800.
65. Liu Q and Linney E (1993) The mouse retinoid-X receptor-γ gene: genomic organization and evidence for functional isoforms. Mol Endocrinol 7:651-658.
66. Lowe MN and Plosker GL (2000) Bexarotene. Am J Clin Dermatol 1:245-250; discussion 251-252.
67. Luria A and Furlow JD (2004) Spatiotemporal retinoid-X receptor activation detected in live vertebrate embryos. Proc Natl Acad Sci USA 101:8987-8992.
68. Mader S, Chen JY, Chen Z, White J, Chambon P, and Gronemeyer H (1993) The patterns of binding of RAR, RXR and TR homo- and heterodimers to direct repeats are dictated by the binding specificities of the DNA binding domains. EMBO (Eur Mol Biol Organ) J 12:5029-5041.
69. Mangelsdorf DJ, Borgmeyer U, Heyman RA, Zhou JY, Ong ES, Oro AE, Kakizuka A, and Evans RM (1992) Characterization of three RXR genes that mediate the action of 9-cis retinoic acid. Genes Dev 6:329-344.
70. Mangelsdorf DJ, Ong ES, Dyck JA, and Evans RM (1990) Nuclear receptor that identifies a novel retinoic acid response pathway. Nature (Lond) 345:224-229.
71. Mangelsdorf DJ, Umesono K, Kliewer SA, Borgmeyer U, Ong ES, and Evans RM (1991) A direct repeat in the cellular retinol-binding protein type II gene confers differential regulation by RXR and RAR. Cell 66:555-561.
72. Mark M and Chambon P (2003) Functions of RARs and RXRs in vivo: genetic dissection of the retinoid signaling pathway. Pure Appl Chem 75:1709-1732.
73. Mark M, Ghyselinck NB, and Chambon P (2006) Function of retinoid nuclear receptors: lessons from genetic and pharmacological dissections of the retinoic acid signalling pathway during mouse embryogenesis. Annu Rev Pharmacol Toxicol 46:451-480.
74. Mascrez B, Ghyselinck NB, Watanabe M, Annicotte JS, Chambon P, Auwerx J, and Mark M (2004) Ligand-dependent contribution of RXRβ to cholesterol homeostasis in Sertoli cells. EMBO Rep 5:285-290.
75. Mascrez B, Mark M, Krezel W, Dupe V, LeMeur M, Ghyselinck NB, and Chambon P (2001) Differential contributions of AF-1 and AF-2 activities to the developmental functions of RXRα. Development 128:2049-2062.
76. Mertz JR, Shang E, Piantedosi R, Wei S, Wolgemuth DJ, and Blaner WS (1997) Identification and characterization of a stereospecific human enzyme that catalyzes 9-cis-retinol oxidation: a possible role in 9-cis-retinoic acid formation. J Biol Chem 272:11744-11749.
77. Metzger D, Li M, and Chambon P (2005) Targeted somatic mutagenesis in the mouse epidermis. Methods Mol Biol 289:329-340.
78. Michaelis S, Cozzio A, Kempf W, Graf P, Burg G, and Dummer R (2004) Combination of bexarotene and psoralen-UVA therapy in a patient with mycosis fungoides. Dermatology 209:72-74.
79. Michellys PY, Ardecky RJ, Chen JH, Crombie DL, Etgen GJ, Faul MM, Faulkner AL, Grese TA, Heyman RA, Karanewsky DS, et al. (2003) Novel (2E,4E,6Z)-7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetes. J Med Chem 46:2683-2696.
80. Mukherjee R, Davies PJ, Crombie DL, Bischoff ED, Cesario RM, Jow L, Hamann LG, Boehm MF, Mondon CE, Nadzan AM, et al. (1997) Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature (Lond) 386:407-410.
81. Nagata T, Kanno Y, Ozato K, and Taketo M (1994) The mouse Rxrb gene encoding RXRβ: genomic organization and two mRNA isoforms generated by alternative splicing of transcripts initiated from CpG island promoters. Gene 142:183-189.
82. Perlmann T and Jansson L (1995) A novel pathway for vitamin A signaling mediated by RXR heterodimerization with NGFI-B and NURR1. Genes Dev 9:769-782.
83. γ and glucose homeostasis. Annu Rev Nutr 22:167-197.
84. Reginato MJ and Lazar MA (1999) Mechanisms by which thiazolidinediones enhance insulin action. Trends Endocrinol Metab 10:9-13.
85. Renaud JP, Rochel N, Ruff M, Vivat V, Chambon P, Gronemeyer H, and Moras D (1995) Crystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid. Nature (Lond) 378:681-689.
86. Repa JJ, Turley SD, Lobaccaro JA, Medina J, Li L, Lustig K, Shan B, Heyman RA, Dietschy JM, and Mangelsdorf DJ (2000) Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science (Wash DC) 289:1524-1529.
87. Romert A, Tuvendal P, Simon A, Dencker L, and Eriksson U (1998) The identification of a 9-cis retinol dehydrogenase in the mouse embryo reveals a pathway for synthesis of 9-cis retinoic acid. Proc Natl Acad Sci USA 95:4404-4409.
88. Rowe A, Eager NS, and Brickell PM (1991) A member of the RXR nuclear receptor family is expressed in neural-crest-derived cells of the developing chick peripheral nervous system. Development 111:771-778.
89. Roy B, Taneja R, and Chambon P (1995) Synergistic activation of retinoic acid (RA)-responsive genes and induction of embryonal carcinoma cell differentiation by an RA receptor α (RAR α)-, RAR β-, or RAR γ-selective ligand in combination with a retinoid X receptor-specific ligand. Mol Cell Biol 15:6481-6487.
90. Schulman IG, Juguilon H, and Evans RM (1996) Activation and repression by nuclear hormone receptors: hormone modulates an equilibrium between active and repressive states. Mol Cell Biol 16:3807-3813.
91. Schulman IG, Li C, Schwabe JW, and Evans RM (1997) The phantom ligand effect: allosteric control of transcription by the retinoid X receptor. Genes Dev 11:299-308.
92. Shen Q, Cline GW, Shulman GI, Leibowitz MD, and Davies PJ (2004) Effects of rexinoids on glucose transport and insulin-mediated signaling in skeletal muscles of diabetic (db/db) mice. J Biol Chem 279:19721-19731.
93. Shulman AI, Larson C, Mangelsdorf DJ, and Ranganathan R (2004) Structural determinants of allosteric ligand activation in RXR heterodimers. Cell 116:417-429.
94. Shulman AI and Mangelsdorf DJ (2005) Retinoid X receptor heterodimers in the metabolic syndrome. N Engl J Med 353:604-615.
95. Smit JV, Franssen ME, de Jong EM, Lambert J, Roseeuw DI, De Weert J, Yocum RC, Stevens VJ, and van De Kerkhof PC (2004) A phase II multicenter clinical trial of systemic bexarotene in psoriasis. J Am Acad Dermatol 51:249-256.
96. Solomin L, Johansson CB, Zetterstrom RH, Bissonnette RP, Heyman RA, Olson L, Lendahl U, Frisen J, and Perlmann T (1998) Retinoid-X receptor signalling in the developing spinal cord. Nature (Lond) 395:398-402.
97. Standeven AM, Beard RL, Johnson AT, Boehm MF, Escobar M, Heyman RA, and Chandraratna RA (1996) Retinoid-induced hypertriglyceridemia in rats is mediated by retinoic acid receptors. Fundam Appl Toxicol 33:264-271.
98. Sucov HM, Dyson E, Gumeringer CL, Price J, Chien KR, and Evans RM (1994) RXRα mutant mice establish a genetic basis for vitamin A signaling in heart morphogenesis. Genes Dev 8:1007-1018.
99. Sucov HM, Izpisua-Belmonte JC, Ganan Y, and Evans RM (1995) Mouse embryos lacking RXRα are resistant to retinoic-acid-induced limb defects. Development 121:3997-4003.
100. Szanto A, Narkar V, Shen Q, Uray IP, Davies PJ, and Nagy L (2004) Retinoid X receptors: X-ploring their (patho)physiological functions. Cell Death Differ 11 (Suppl 2):S126-S143.
101. Thacher SM, Vasudevan J, and Chandraratna RA (2000) Therapeutic applications for ligands of retinoid receptors. Curr Pharm Des 6:25-58.
102. 3 and inhibited by 9-cis-retinoic acid: evidence for allosteric receptor interactions. J Biol Chem 273:8483-8491.
103. Tontonoz P, Graves RA, Budavari AI, Erdjument-Bromage H, Lui M, Hu E, Tempst P, and Spiegelman BM (1994) Adipocyte-specific transcription factor ARF6 is a heterodimeric complex of two nuclear hormone receptors, PPARγ and RXRα. Nucleic Acids Res 22:5628-5634.
104. Vivat-Hannah V, Bourguet W, Gottardis M, and Gronemeyer H (2003) Separation of retinoid X receptor homo- and heterodimerization functions. Mol Cell Biol 23:7678-7688.
105. Vivat-Hannah V and Zusi FC (2005) Retinoids as therapeutic agents: today and tomorrow. Mini Rev Med Chem 5:755-760.
106. Wan YJ, An D, Cai Y, Repa JJ, Hung-Po Chen T, Flores M, Postic C, Magnuson MA, Chen J, Chien KR, et al. (2000) Hepatocyte-specific mutation establishes retinoid X receptor α as a heterodimeric integrator of multiple physiological processes in the liver. Mol Cell Biol 20:4436-4444.
107. Westin S, Kurokawa R, Nolte RT, Wisely GB, McInerney EM, Rose DW, Milburn MV, Rosenfeld MG, and Glass CK (1998) Interactions controlling the assembly of nuclear-receptor heterodimers and co-activators. Nature (Lond) 395:199-202.
108. Yu VC, Delsert C, Andersen B, Holloway JM, Devary OV, Naar AM, Kim SY, Boutin JM, Glass CK, and Rosenfeld MG (1991) RXRβ: a coregulator that enhances binding of retinoic acid, thyroid hormone, and vitamin D receptors to their cognate response elements. Cell 67:1251-1266.
109. Zhang C and Duvic M (2003) Retinoids: therapeutic applications and mechanisms of action in cutaneous T-cell lymphoma. Dermatol Ther 16:322-330.
110. Zhang J, Hu X, and Lazar MA (1999) A novel role for helix 12 of retinoid X receptor in regulating repression. Mol Cell Biol 19:6448-6457.
111. Zhang J, Zamir I, and Lazar MA (1997) Differential recognition of liganded and unliganded thyroid hormone receptor by retinoid X receptor regulates transcriptional repression. Mol Cell Biol 17:6887-6897.
112. Zomer AW, van Der Burg B, Jansen GA, Wanders RJ, Poll-The BT, and van Der Saag PT (2000) Pristanic acid and phytanic acid: naturally occurring ligands for the nuclear receptor peroxisome proliferator-activated receptor α. J Lipid Res 41:1801-1807.